Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via insulin-like growth...

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Picropodophyllin (PPP) is an investigational anticancer drug for non-small cell lung cancer (NSCLC).
• Previous studies indicated PPP suppresses Insulin-like Growth Factor-1 Receptor (IGF-1R) signaling and induces G2/M cell cycle arrest.
• The precise mechanisms underlying PPP's anticancer effects require further elucidation.

Purpose of the Study:

• To identify the specific molecular mechanisms by which Picropodophyllin (PPP) exerts its anticancer effects.
• To investigate whether PPP's mechanism of action is dependent on IGF-1R signaling.
• To determine the specificity of PPP's effects on cancer cells versus normal cells.

Main Methods:

• Utilized human cancer cell lines and an A549 xenograft mouse model.
• Assessed cell cycle progression, CDK1 activation, and mitotic spindle formation.
• Investigated PPP's effects in IGF-1R-depleted and IGF-1R-null cancer cells.
• Analyzed microtubule dynamics by measuring soluble and spindle-associated tubulin levels.

Main Results:

• Identified an IGF-1-independent mechanism of PPP action leading to prometaphase arrest.
• Observed mitotic block in cancer cell lines and xenografts, but not in normal hepatocytes or mouse tissues.
• Demonstrated prominent CDK1 activation and prevention of centrosome separation, resulting in monopolar mitotic spindles.
• Showed PPP interferes with microtubule dynamics, increasing soluble tubulin and decreasing spindle-associated tubulin.

Conclusions:

• Picropodophyllin (PPP) induces mitotic catastrophe via an IGF-1R-independent pathway, specifically targeting tumor cells.
• The drug disrupts microtubule dynamics and centrosome separation, leading to prometaphase arrest.
• These findings reveal a novel mechanism for PPP's antitumor activity, distinct from IGF-1R suppression.